Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
Michaela Waibel(Peter MacCallum Cancer Centre), Ricky W. Johnstone(The University of Melbourne)
Cited by 134
Related Papers
New and emerging HDAC inhibitors for cancer treatment
|Journal of Clinical Investigation|2014|1.4k
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
|Cell Reports|2017|297
Functional Crosstalk between Type I and II Interferon through the Regulated Expression of STAT1
|PLoS Biology|2010|196
A Novel c-Jun-dependent Signal Transduction Pathway Necessary for the Transcriptional Activation of Interferon γ Response Genes
|Journal of Biological Chemistry|2006|62